United Kingdom

People: Allogene Therapeutics Inc (ALLO.OQ)

ALLO.OQ on NASDAQ Stock Exchange Global Select Market

13 Sep 2019
Change (% chg)

$-0.20 (-0.66%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Witte, Owen 

Dr. Owen N. Witte, M.D. serves as Independent Director of the Company. Dr. Witte previously served as a member of the board of directors of Kite from March 2017 until October 2017. Dr. Witte joined the UCLA faculty in 1980, where he is presently a University Professor of microbiology, immunology and molecular genetics, the UCLA David Saxon Presidential Chair in Developmental Immunology and the director of the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research. Dr. Witte was appointed a University Professor by the University of California Board of Regents, an honor reserved for scholars of the highest international distinction. Dr. Witte is a member of the National Academy of Sciences, the American Academy of Arts and Sciences, and the National Academy of Medicine. Dr. Witte currently serves on several editorial and advisory boards. He previously served on the board of directors for the American Association for Cancer Research. He was appointed by President Obama to the President’s Cancer Panel. Dr. Witte holds a bachelor’s degree from Cornell University and an M.D. from Stanford University. He completed postdoctoral research at the Massachusetts Institute of Technology. Our board of directors believes Dr. Witte’s expertise and experience in cancer research, his experience in academia and his educational background provide him with the qualifications and skills to serve on our board of directors.

Basic Compensation

Total Annual Compensation, USD 20,000
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 288,488
Fiscal Year Total, USD 308,488

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Arie Belldegrun


David Chang


Joshua Kazam


Eric Schmidt


Alison Moore


David Bonderman

As Of  31 Dec 2018